



Ein Unternehmen der
Johann Wolfgang Goethe-Universität Frankfurt am Main



TRANSLATION AN DER GOETHE UNIVERSITÄT - VOM WISSEN ZUR INNOVATION -

THIRD MISSION

GESELLSCHAFTLICHE VERANTWORTUNG VON
UNIVERSITÄTEN –
MÖGLICHKEITEN UND GRENZEN

TRILATERALE TAGUNG

ÖSTERREICHISCHER UNIVERSITÄTSPROFESSOR/INNENVERBAND (UPV)
DEUTSCHER HOCHSCHULVERBAND (DHV)
VEREINIGUNG DER SCHWEIZERISCHEN HOCHSCHULDOZIERENDEN (VSH)

FREITAG, 18. OKTOBER 2019
GROSSER FESTSAAL DER UNIVERSITÄT WIEN
UNIVERSITÄTSRING 1

Dr. Martin Raditsch



Society benefits from basic research



INNOVECTIS

INNOVECTIS is the technology transfer company of the Goethe University. We serve as an important link between academia and industry.

Service for Scientists


How can I protect and commercialize my research results? INNOVECTIS helps scientists with all questions concerning technology transfer.

Service for Companies

INNOVECTIS provides access for companies to research results and cooperation opportunities with the Goethe University.




Societal Impact





KT - Embedded in the Third Mission





Innovectis transfers knowledge & technology



Technology & Knowledge Transfer


Innovectis GmbH

100% subsidiary

- IP Protection
- IP Exploitation
- Collaborative research
- Spin Offs
- Incubation
- Exchange



Knowledge Transfer Eco System





Economic KPIs – Is this enough?



Income TT 2017: 2,1 Mio €

- Income Licences 2017: 1.681.000 €
(netto)
(11 agreements)
- Future expected income from closed agreements

23 Mio € until 2024

50 Mio € until 2034



Societal Impact trough KT

NEU Standardisierte mesenchymale Stromazellen aus gepoolten Knochenmarkzellen – für Ihre steroid-refraktären GVHD-Patienten nach allogener Stammzelltransplantation.

**Auf Patrouille
in der Blutbahn**

OBNI TIX[®]
INFUSIONSSUSPENSION

STANDARDISIERTE MESENCHYMALE STROMAZELLEN

With the help of our
licensing partner
Medac,
hundreds of lives could
be saved within the
first year!



We have the choice, haven't we...?





Model

Goals:

- Institutions shall participate on the economic success
- Enable spin-offs good starting conditions
- Keep certain influence on the technology and the spin-off
- Scientists can join the spin-off or can stay at the institution
- Thoughts about liability, corporate governance, exits (maybe place shares in a separate holding structure)



*Technology presumes there's just one right way
to do things and there never is.*

Robert M. Pirsig



Thanks!

Dr. Martin Raditsch
October 18, 2019